Combination of cdk4/6 inhibitor combined with her2 inhibitor for gastric cancer treatment

Abstract

The invention discloses CDK4 / 6 inhibitor and HER2 inhibitor combination for gastric cancer treatment and application of a CDK4 / 6 inhibitor and a HER2 inhibitor to preparation of a composition for treatment of HER2 positive gastric cancer patients with drug tolerance. In gastric cancer clinical research history, the patients with drug tolerance after first-line treatment are slightly benefited no matter which drug / scheme is adopted. Excellent benefits achieved by use of the treatment combination are rare, and the treatment combination is put forward for the first time on the basis of preclinical study and verified through clinical researches on patients and is a landmark major breakthrough in the field of gastric cancers.

Description

technical field

[0001] The present invention relates to the combination of CDK4 / 6 inhibitor combined with HER2 inhibitor for the treatment of gastric cancer. Background technique

[0002] Asia is the region with the highest incidence of gastric cancer in the world, and China accounts for 47% of the world's new cases each year. The latest Chinese tumor registration statistics show that the incidence and mortality of gastric cancer rank among the top three among malignant tumors in the country, seriously endangering the health of Chinese people. About 80% of Chinese gastric cancer patients are diagnosed with late disease stage (distant metastasis or locally advanced stage), who lose the chance of radical surgery or have a high recurrence and metastasis rate after surgery, and drug therapy is the main treatment for patients with late stage. In the past few decades, chemotherapy has been the cornerstone of gastric cancer drug treatment, but the limited benefits and high toxicit...

Images